In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice

Anti-Cancer Drugs

Volumn 23, Issue 1, 2012, Pages 90-97

  Manea, Marilena ^a   Tóvári, József ^b   Tejeda, Miguel ^b   Schulcz, Ákos ^b   Kapuvári, Bence ^b   Vincze, Borbála ^b   Mezo, Gábor ^c  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^c EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

colon cancer; daunorubicin GnRH III derivative conjugates; gonadotropin releasing hormone III; in vivo antitumour activity; in vivo toxicity; oxime bond; targeted cancer chemotherapy

Indexed keywords

DAUNORUBICIN; DAUNORUBICIN GONADORELIN CONJUGATE; GONADORELIN DERIVATIVE; TETRAPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG CONJUGATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, SCID; PYRROLIDONECARBOXYLIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82555166976     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32834bb6b4     Document Type: Article

References (28)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19:1893-1907.
2. Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer 2010; 116:4354-4359.
3. Yiu HY, Whittemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. Int J Cancer 2004; 109:777-781. (Pubitemid 38405628)
4. Aranha O, Benson AB III. Adjuvant therapy for colon cancer. Curr Gastroenterol Rep 2007; 9:415-421.
5. Singh Y, Palombo M, Sinko PJ. Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 2008; 15:1802-1826.
6. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003; 24:389-427. (Pubitemid 37056239)
7. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumours. Eur J Endocrinol 1999; 141:1-14. (Pubitemid 29370830)
8. Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoural hormone receptors. Trends Endocrinol Metab 2004; 15:300-310. (Pubitemid 39193184)
9. Mezo G, Manea M. Receptor-mediated tumour targeting based on peptide hormones. Expert Opin Drug Deliv 2010; 7:79-96.
10. Bajusz S, Janáky T, Csernus VJ, Bokser L, Fekete M, Srkalovic G, et al. Highly potent analogues of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA 1989; 86:6318-6322. (Pubitemid 19210643)
11. Nagy A, Schally AV, Armatis P, Szepesházi K, Halmos G, Kov́cs M, et al. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA 1996; 93:7269-7273. (Pubitemid 26243538)
12. Nagy A, Schally AV. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod 2005; 73:851-859. (Pubitemid 41507486)
13. Szepesházi K, Schally AV, Halmos G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int J Oncol 2007; 30:1485-1492.
14. Kov́cs M, Szepesházi K, Schally AV. Endocrine and antineoplastic effects of antagonistic and cytotoxic analogs of luteinising hormone-releasing hormone. In: Kov́cs M, Merchenhalter I, editors. Neuropeptides and peptide analogs. Kerela, India: Research Signpost. 2009; pp. 33-57.
15. Sower SA, Chiang Y-C, Lovas S, Conlon JM. Primary structure and biological activity of a third gonadotropin-releasing hormone from lamprey brain. Endocrinology 1993; 132:1125-1131. (Pubitemid 23068627)
16. Millar RP. GnRHs and GnRH receptors. Anim Reprod Sci 2005; 88: 5-28. (Pubitemid 41225341)
17. Lovas S, Pályi I, Vincze B, Horváth J, Kov́cs M, Mezo I, et al. Direct anticancer activity of gonadotropin-releasing hormone-III. J Pept Res 1998; 52:384-389. (Pubitemid 29018332)
18. Kov́cs M, Vincze B, Horváth JE, Seprodi J. Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs. Peptides 2007; 28:821-829. (Pubitemid 46349333)
19. Mezo I, Lovas S, Pályi I, Vincze B, Kálnay A, Turi G, et al. Synthesis of gonadotropin-releasing hormone III analogs. Structure-anti-tumour activity relationships. J Med Chem 1997; 40:3353-3358.
20. Mezo G, Czajlik A, Manea M, Jakab A, Farkas V, Majer Z, et al. Structure, enzymatic stability and anti-tumour activity of sea lamprey GnRH-III and its dimer derivatives. Peptides 2007; 28:806-820. (Pubitemid 46349329)
21. Pályi I, Vincze B, Lovas S, Mezo I, Pató J, Kálnay A, et al. Gonadotropinreleasing hormone analogue conjugates with strong selective anti-tumour activity. Proc Natl Acad Sci U S A 1999; 96:2361-2366. (Pubitemid 29117920)
22. Szabó I, Manea M, Orb́n E, Cśmpai A, Bosze S, Szabó R, et al. Development of an oxime bond containing daunorubicin-gonadotropinreleasing hormone-III conjugate as a potential anticancer drug. Bioconjug Chem 2009; 20:656-665.
23. Orb́n E, Mezo G, Schlage P, Csík G, Kulic Z, Ansorge P, et al. In vitro degradation and anti-tumour activity of oxime bond-linked daunorubicin- GnRH-III bioconjugates and DNA-binding properties of daunorubicin-amino acid metabolites. Amino Acids 2010; 41:469-483.
24. Tomayko MM, Reynolds CP. Determination of subcutaneous tumour size in athymic (nude) mice. Cancer Chemother Pharmocol 1989; 24: 148-154. (Pubitemid 19163397)
25. Mezo G, Manea M, Szabó I, Vincze B, Kov́cs M. New derivatives of GnRH as potential anticancer therapeutic agents. Curr Med Chem 2008; 15:2366-2379.
26. Mezo G, Orb́n E, Szabó I, Hegedus R, Bosze S, Tejeda M, et al. GnRH based drug delivery systems for targeted tumour therapy. Collections Symp Series 2009; 11:72-76.
27. Kubota T, Yamaguchi H, Watanabe M, Yamamoto T, Takahara T, Takeuchi T, et al. Growth of human tumour xenografts in nude mice and mice with severe combined immunodeficiency (SCID). Surg Today 1993; 23:375-377. (Pubitemid 23107579)
28. Furukawa T, Kubota T,Watanabe M, Nishibori H, Kuo T-H, Saikawa Y, et al. A suitable model for experimental liver metastasis of human colon cancer xenografts using mice with severe combined immunodeficiency. J Surg Oncol 1993; 52:64-67. (Pubitemid 23032113)